Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cycloferon for Post-exposure Prophylaxis of ARVI and Influenza
NCT06183229Phase 3Completed
- Sponsor
- POLYSAN
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cridanimod in influenza, acute respiratory viral infection (ARVI), sponsored by POLYSAN. Started Sep 2023; status: completed.
02
Drugs
cridanimod
03
Conditions
influenzaacute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT06183229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06183229.